-
ASCO breast cancer guideline update: HER2 low expression breast cancer ushered in a new program!
Time of Update: 2022-09-09
Research InterpretationThe recommended evidence for DS8201 in the guideline is based on DESTINY- Breast04 , a phase III, two-group, open-label, randomized, multicenter clinical trial: Screenshot of study publication Patients with metastatic breast cancer with low HER2 expression, randomized 2:1 to receive DS8201 or physician's choice chemotherapy (TPC, limited to capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) .
-
Surufatinib Biliary Tumor Excellence Forum
Time of Update: 2022-09-09
Professor Sun Yuling of the First Affiliated Hospital of Zhengzhou University combined the comprehensive treatment of the above three wonderful cases, talked about the heterogeneity of tumors and then looked forward to the future direction of BTC diagnosis and treatment .
-
DS-8201 is not the endpoint: the development of camptothecin and its derivative ADC and strategies to enhance therapeutic efficacy
Time of Update: 2022-09-09
The rapid development of methods to improve the stability of thioether bonds approved by the FDA/ongoing clinical trials that represent the binding of TOP1-ADCTOP1 inhibitors to antibodies reflects the direction of modern ADC therapy (Table 2).
-
【Cell Discovery】Qin Wenxin's team at Shanghai Jiaotong University proposed a new treatment strategy for hepatocellular carcinoma: EGFR blockade combined with cabozantinib to improve clinical efficacy
Time of Update: 2022-09-09
The researchers also tested the combined effects of cabotinib and two FDA-approved EGFR inhibitors, including gefitinib and afatinib.
The researchers also tested the combined effects of cabotinib and two FDA-approved EGFR inhibitors, including gefitinib and afatinib.
-
Shengnuo Pharmaceutical siRNA drugs released Phase II clinical data, domestic small nucleic acid drugs or will enter the fast lane
Time of Update: 2022-09-09
Recommended reading: Shengnuo Pharmaceutical skin cancer siRNA drug Phase II clinical realization of 100% complete remission, siRNA technology or will usher in a golden decade?In addition, in recent days, Sunno Pharma also announced that the company is promoting RNAi therapy based on the GalAhead™ delivery platform for the treatment of complement-mediated related diseases.
-
Machine learning reveals cellular morphological subtypes and molecular interpretations of LGG
Time of Update: 2022-09-09
Recently, Xiao-Ping Liu of the Department of Biological Systems and Engineering of lawrence Berkeley National Laboratory in the United States has applied machine learning to integrate and verify clinical data and database data, conduct clinical biological evaluation, construct cell morphological background characterization, and apply immunohistochemistry to develop and validate machine learning frameworks for cell morphology measurement subtypes, which are used to discover cell morphological subtypes of LGG related to specific molecular changes, immune microenvironments, prognosis and therapeutic responses.
-
Evidence-Based Medicine is worth reading!
Time of Update: 2022-09-09
Analysis conclusionBased on this SR, for AS protocols without MRI, the investigators recommend: (1) Low-risk patients with International Society of Urology Pathology Classification (ISUP) 2, or a single intermediate-risk factor (excluding ISUP 3) (2) Patients with low-risk but more extensive involvement (number of positive needles ≥ 3 or CI > 50%) PCa patients in ISUP grade 1 should be closely monitored, while similar patients in ISUP grade 2 should be closely monitored.
-
Frontier different ways to enter the systemic circulation!
Time of Update: 2022-09-09
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamBecause cancer cells in a tumor have different abnormally activated information pathways, it is usually necessary to simultaneously inhibit multiple targets with different drugs to effectively inhibit tumor growth .
-
CAR-NK cell therapy targeting CD38 expresses powerful anti-tumor ability!
Time of Update: 2022-09-09
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamONK Therapeutics today announced the first in vivo trial data of its fully humanized, CD38-targeting chimeric antigen receptor (CAR)-natural killer (NK) cell therapy ONKT102 .
-
New progress in neoadjuvant therapy for lung cancer!
Time of Update: 2022-09-09
OS resultsAnalysis of OS according to pCR status The latest survival data from the NADIM ll study confirmed the efficacy of nivolumab in combination with platinum-based chemotherapy in neoadjuvant treatment of resectable stage IIIA NSCLC .
-
JCO: Immunocombination therapy improves OS and ORR in advanced sarcomas and solid tumors
Time of Update: 2022-09-09
Download the Doctor Station App and subscribe anytime, anywhere~*For medical professional reading reference only1 minute a day, give you professional "talks" in the tumor circle!
Download the Doctor Station App and subscribe anytime, anywhere~*For medical professional reading reference only1 minute a day, give you professional "talks" in the tumor circle!
-
JCO Voice of China｜Professor Wang Changli's Team: EVEN Research Announces OS Update Results
Time of Update: 2022-09-09
9 months in the erlotinib and chemotherapy groups, respectively, and 5 years in the intent-to-treat (ITT) and per-protocol (PPP) populations The DFS rates were 48.
9 months in the erlotinib and chemotherapy groups, respectively, and 5 years in the intent-to-treat (ITT) and per-protocol (PPP) populations The DFS rates were 48.
-
Three different subtypes of lung cancer appear in one patient, what's going on?
Time of Update: 2022-09-09
For example, the 76-year-old patient in the following case, who works as a parking attendant, has been diagnosed with three different types of lung cancer, which are multiple primary lung cancers (MPLC) .
-
Oncology Cardiology Guidelines: Working to Reduce Cardiovascular Toxicity Associated with Cancer Treatment ESC 2022
Time of Update: 2022-09-09
The expert group summarized the diagnosis and treatment and prevention strategies of CTR-CVT in the central illustration of the guidelines (Figure 1): Figure 1: Diagnosis and treatment and prevention strategies for CTR-CVTBefore starting cancer treatment with known cardiovascular toxicity characteristics, the oncology cardiology team should identify and treat cardiovascular risk factors and pre-existing CVD, and develop appropriate prevention and monitoring plans to identify and manage potential cardiovascular complications early.
-
Experts talk about | new options, more benefits: welcome to the market! Bugotinib pilots a new course of ALK-positive advanced NSCLC treatment
Time of Update: 2022-09-09
On this occasion, Professor Wu Yilong of Guangdong Provincial People's Hospital and Professor Lu Shun of the Chest Hospital Affiliated to Shanghai Jiao Tong University were invited to share the current status of ALK-positive NSCLC diagnosis and treatment, introduce the clinical value and listing significance of bugotinib and the future exploration direction of precision treatment of lung cancer.
-
For patients with advanced nasopharyngeal carcinoma who failed platinum-based chemotherapy, nivolumab + gemcitabine showed good efficacy
Time of Update: 2022-09-09
A phase II study from the journal Clin Cancer Res evaluated the efficacy and safety of nivolumab in combination with gemcitabine in patients with nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy .
-
Professor Deng Qi: Cellular immunotherapy and targeted drug therapy have become the "mainstay" of relapsed/refractory lymphoma treatment
Time of Update: 2022-09-09
Lymphoma is a malignant tumor that originates from lymph nodes and lymphoid tissue, and is one of the top ten malignant tumors common in China. The etiology and pathogenesis of lymphoma are not fully
-
The Lancet: The first domestic bivalent HPV vaccine Phase 3 clinical results released, 100% prevention of cervical precancerous lesions
Time of Update: 2022-09-09
The results showed that the HPV vaccine showed extremely high protective efficacy in preventing HPV 16/18-related lesions and persistent infection in women aged 18-45 during the 66-month follow-up period .
-
What to do if EGFR targeted drugs are resistant? Combination therapies are worth trying
Time of Update: 2022-09-09
Through the domestic PD-1 inhibitors sindilizumab, bevacizumab biosimilars, pemetrexed and cisplatin, it can also bring better benefits to lung cancer patients who are targeted drug-resistant.
Through the domestic PD-1 inhibitors sindilizumab, bevacizumab biosimilars, pemetrexed and cisplatin, it can also bring better benefits to lung cancer patients who are targeted drug-resistant.
-
New Targets, New Hopes - These drugs are "hot" at the 2022 WCLC conference!
Time of Update: 2022-09-08
A comprehensive analysis of 372-001 (EudraCT 2012-000148-8), demonstrating its efficacy in patients with ROS1 fusion-positive (ROS1-fp) NSCLC and central nervous system (CNS) activity, showed an objective response rate (ORR) of 67% (n=108/161; data cut-off date: May 1, 2019; median survival follow-up time: 15.
